Quantitative ligandomics for systematic identification of therapeutic ligands
US10794901B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 2, 2018 |
| Grant date | Oct 6, 2020 |
| Priority date | — |
| Expiry date | Jan 2, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2570/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is directed to methods for developing novel anti-angiogenic therapies. This invention discovers secretogranin III (Scg3) not only as a novel disease-selective angiogenic factor but also as a target for anti-angiogenic therapy of vascular diseases. Inhibitors against Scg3 can treat diabetic retinopathy, wet age-related macular degeneration, retinopathy of prematurity, retinal vein occlusion, neovascular glaucoma, corneal neovascularization, and cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.